A randomized, placebo‐controlled study to evaluate safety and pharmacokinetics of ART‐001 with a novel oral pediatric formulation in healthy subjects

• Váldodahkkit: Akira Tanaka (Dahkki), Naoto Uemura (Dahkki), Kanako Kuniyeda (Dahkki), Haruhi Ando (Dahkki), Toshinori Higashi (Dahkki), Hiroshi Nagabukuro (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2023-10-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract ART‐001 is an orally available selective PI3Kα inhibitor currently being developed for the treatment of slow‐flow vascular malformations (SFVMs). ART‐001 used to be developed for advanced solid tumors, but was suspended largely due to significant pharmacokinetic (PK) variability in its phas...